Scripps Institute Spin-Out Company Raises $3 Million
UF startup Myosin Therapeutics, a biotechnology company developing medications to treat brain cancer and methamphetamine addiction, secured $3 million in seed funding.
Mutations Disrupt Touch-Based Learning, Study Finds
UF researchers, supported by the National Institutes of Health, have found that the Syngap1 gene plays a crucial role in touch-based perception, while certain mutations can lead to mixed signals.
Myosin Therapeutics Closes Second Seed Round To Advance Clinical Trials for Innovative Cancer and Neuroscience Therapies
UF startup Myosin Therapeutics, Inc., a biotechnology company developing novel therapies for cancer and neurological disorders, has closed its second seed funding round, raising over $3 million to supplement significant investment from the National Institutes of Health.
The Wertheim UF Scripps Institute, UF Medicinal Chemistry Target Incurable Diseases
University of Florida researchers with expertise in drug discovery and chemistry are advancing potential treatments for challenging diseases via a new collaborative initiative.
UF Scientist’s Parkinson’s Work Selected for Innovative Drug Development Effort
University of Florida chemist Matthew Disney, Ph.D., was selected for an ambitious two-year effort to move promising Parkinson’s disease discoveries to patients.